| Assay ID | Title | Year | Journal | Article |
|---|
| AID1327644 | Inhibition of CYP2C19 in human liver microsomes using mephenytoin as substrate in presence of NADPH by LC-MS/MS analysis | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
| Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors. |
| AID79470 | Cytotoxic activity against HA22T liver cancer cell line | 2004 | Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
| Synthesis and in vitro cytotoxicity of 5-substituted 2-cyanoimino-4-imidazodinone and 2-cyanoimino-4-pyrimidinone derivatives. |
| AID103209 | Cytotoxic activity against MCF breast cancer cell line | 2004 | Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
| Synthesis and in vitro cytotoxicity of 5-substituted 2-cyanoimino-4-imidazodinone and 2-cyanoimino-4-pyrimidinone derivatives. |
| AID1074215 | Antiproliferative activity against human A2780 cells after 72 hrs by sulforhodamine B assay in presence of nicotinamide mononucleotide | 2014 | Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
| Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT). |
| AID1564559 | Toxicity in Crl:CD Sprague-Dawley rat heart assessed as hypereosinophilia at 200 mg/kg, po administered once daily via gavage for 5 days by hematoxylin and eosin staining based microscopic analysis | 2019 | European journal of medicinal chemistry, Nov-01, Volume: 181 | Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group. |
| AID1454318 | Antiproliferative activity against human PC3 cells assessed as reduction in cell viability incubated for 5 days by Cell-titer Glo reagent based assay | 2017 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
| SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT). |
| AID1454333 | Aqueous solubility of the compound | 2017 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
| SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT). |
| AID1564561 | Antitumor activity against mouse 4T1 cells implanted in BALB/c mouse assessed as reduction in tumour volume at 10 mg/kg, ip bid for 12 days by vernier caliper method | 2019 | European journal of medicinal chemistry, Nov-01, Volume: 181 | Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group. |
| AID81550 | Cytotoxic activity against HepG2 liver cancer cell line | 2004 | Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
| Synthesis and in vitro cytotoxicity of 5-substituted 2-cyanoimino-4-imidazodinone and 2-cyanoimino-4-pyrimidinone derivatives. |
| AID249536 | Inhibition of NYH Cell line | 2005 | Bioorganic & medicinal chemistry letters, May-16, Volume: 15, Issue:10
| EB1627: a soluble prodrug of the potent anticancer cyanoguanidine CHS828. |
| AID236940 | Half life value in human serum; nd=Not determined | 2005 | Bioorganic & medicinal chemistry letters, May-16, Volume: 15, Issue:10
| EB1627: a soluble prodrug of the potent anticancer cyanoguanidine CHS828. |
| AID767957 | Half life in human | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
| Medicinal chemistry of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors. |
| AID1074217 | Antiproliferative activity against human A2780 cells after 72 hrs by sulforhodamine B assay | 2014 | Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
| Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT). |
| AID1188767 | Cytotoxicity against human MCF cells after 24 hrs by SRB assay | 2014 | European journal of medicinal chemistry, Oct-30, Volume: 86 | Synthesis of novel 1,2,4-triazoles, triazolothiadiazines and triazolothiadiazoles as potential anticancer agents. |
| AID237711 | Solubility at pH-5.5 | 2005 | Bioorganic & medicinal chemistry letters, May-16, Volume: 15, Issue:10
| EB1627: a soluble prodrug of the potent anticancer cyanoguanidine CHS828. |
| AID1057522 | Cytotoxicity against human A2780 cells assessed as growth inhibition after 72 hrs by WST-1 assay | 2013 | Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
| Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship. |
| AID1454319 | Unbound intrinsic clearance in mouse liver microsomes at 0.5 uM in presence of NADPH incubated for 5 to 30 mins by HPLC-MS/MS method | 2017 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
| SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT). |
| AID752617 | Inhibition of Nampt (unknown origin) using NAM/PRPP as substrate preincubated for 15 mins measured after 30 mins | 2013 | Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
| Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors. |
| AID1454320 | Unbound intrinsic clearance in human liver microsomes at 0.5 uM in presence of NADPH incubated for 5 to 30 mins by HPLC-MS/MS method | 2017 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
| SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT). |
| AID1188768 | Cytotoxicity against human WI38 cells after 24 hrs by SRB assay | 2014 | European journal of medicinal chemistry, Oct-30, Volume: 86 | Synthesis of novel 1,2,4-triazoles, triazolothiadiazines and triazolothiadiazoles as potential anticancer agents. |
| AID1327639 | Reversible inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate in presence of NADPH by LC-MS/MS analysis | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
| Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors. |
| AID752616 | Cytotoxicity against human A2780 cells after 72 hrs by SRB assay | 2013 | Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
| Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors. |
| AID765309 | Fraction unbound in human plasma at 5 uM after 4 hrs by LC-MS/MS analysis | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
| Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors. |
| AID1188766 | Cytotoxicity against human HONE1 cells after 24 hrs by SRB assay | 2014 | European journal of medicinal chemistry, Oct-30, Volume: 86 | Synthesis of novel 1,2,4-triazoles, triazolothiadiazines and triazolothiadiazoles as potential anticancer agents. |
| AID767966 | Cytotoxicity against human NYH cells after 3 weeks by clonogenic survival assay | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
| Medicinal chemistry of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors. |
| AID765313 | Metabolic stability in human liver microsomes assessed as compound remaining at 1 uM after 30 mins LC-MS analysis | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
| Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors. |
| AID1074218 | Clearance in human liver microsomes at 1 uM up to 60 mins by LC-MS/MS analysis | 2014 | Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
| Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT). |
| AID81348 | Cytotoxic activity against HONE1 nasopharyngeal carcinoma cell line | 2004 | Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
| Synthesis and in vitro cytotoxicity of 5-substituted 2-cyanoimino-4-imidazodinone and 2-cyanoimino-4-pyrimidinone derivatives. |
| AID765312 | Intrinsic clearance in CD-1 mouse hepatocytes at 1 uM after 10 mins by LC-MS/MS analysis | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
| Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors. |
| AID1564555 | Toxicity in Crl:CD Sprague-Dawley rat retina at 200 mg/kg, po administered once daily for 5 days via gavage by hematoxylin and eosin staining based microscopic analysis | 2019 | European journal of medicinal chemistry, Nov-01, Volume: 181 | Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group. |
| AID1057520 | Cytotoxicity against human MCF-7 cells assessed as growth inhibition after 72 hrs by WST-1 assay | 2013 | Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
| Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship. |
| AID1327638 | Inhibition of NAMPT in human A2780 cells assessed as decrease in cell viability after 72 hrs by SRB assay | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
| Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors. |
| AID765314 | Metabolic stability in mouse liver microsomes assessed as compound remaining at 1 uM after 30 mins LC-MS analysis | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
| Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors. |
| AID237712 | Solubility at pH-7.4 | 2005 | Bioorganic & medicinal chemistry letters, May-16, Volume: 15, Issue:10
| EB1627: a soluble prodrug of the potent anticancer cyanoguanidine CHS828. |
| AID1188763 | Cytotoxicity against human DLD1 cells after 24 hrs by SRB assay | 2014 | European journal of medicinal chemistry, Oct-30, Volume: 86 | Synthesis of novel 1,2,4-triazoles, triazolothiadiazines and triazolothiadiazoles as potential anticancer agents. |
| AID236930 | Half life value at pH-7.4;nd=Not determined | 2005 | Bioorganic & medicinal chemistry letters, May-16, Volume: 15, Issue:10
| EB1627: a soluble prodrug of the potent anticancer cyanoguanidine CHS828. |
| AID53950 | Cytotoxic activity against DLD1 colon cancer cell line | 2004 | Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
| Synthesis and in vitro cytotoxicity of 5-substituted 2-cyanoimino-4-imidazodinone and 2-cyanoimino-4-pyrimidinone derivatives. |
| AID1327641 | Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
| Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors. |
| AID1074222 | Inhibition of C-terminal His-tagged human full-length NAMPT expressed in Escherichia coli Rosetta DE3 using nicotinamide as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins in presence of PRPP | 2014 | Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
| Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT). |
| AID1327643 | Inhibition of CYP1A2 in human liver microsomes using tacrine as substrate in presence of NADPH by LC-MS/MS analysis | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
| Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors. |
| AID765316 | Inhibition of C-terminal His-tagged NAMPT (unknown origin) expressed in Escherichia coli BL21 using nicotinamide as substrate preincubated for 15 mins before substrate addition measured after 30 mins by mass spectrometry-based assay | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
| Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors. |
| AID765308 | Fraction unbound in mouse plasma at 5 uM after 4 hrs by LC-MS/MS analysis | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
| Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors. |
| AID1564551 | Half-life in human | 2019 | European journal of medicinal chemistry, Nov-01, Volume: 181 | Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group. |
| AID1564570 | Toxicity in Crl:CD Sprague-Dawley rat heart assessed as interstitial expansion at 200 mg/kg, po administered once daily for 5 days via gavage by hematoxylin and eosin staining based microscopic analysis | 2019 | European journal of medicinal chemistry, Nov-01, Volume: 181 | Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group. |
| AID216107 | Cytotoxic activity against WI38 normal fibroblast cell line; na=Not active | 2004 | Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
| Synthesis and in vitro cytotoxicity of 5-substituted 2-cyanoimino-4-imidazodinone and 2-cyanoimino-4-pyrimidinone derivatives. |
| AID1327640 | Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate in presence of NADPH by LC-MS/MS analysis | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
| Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors. |
| AID765310 | Apparent permeability across apical to basolateral side in dog MDCK cells at 10 uM by LC-MS/MS analysis | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
| Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors. |
| AID1327637 | Inhibition of human full length C-terminal His6-tagged NAMPT expressed in Escherichia coli Rosetta (DE3) cells using nicotinamide as substrate incubated for 15 mins prior to substrate addition measured after 30 mins in presence of PRPP | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
| Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors. |
| AID1327642 | Inhibition of CYP2D6 in human liver microsomes using dextromethorphan as substrate in presence of NADPH by LC-MS/MS analysis | 2016 | Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
| Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors. |
| AID765311 | Intrinsic clearance in human hepatocytes at 1 uM after 10 mins by LC-MS/MS analysis | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
| Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors. |
| AID765315 | Antiproliferative activity against human A2780 cells assessed as growth inhibition after 72 hrs by SRB-based microplate reader analysis | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
| Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors. |
| AID1188764 | Cytotoxicity against human HA22T cells after 24 hrs by SRB assay | 2014 | European journal of medicinal chemistry, Oct-30, Volume: 86 | Synthesis of novel 1,2,4-triazoles, triazolothiadiazines and triazolothiadiazoles as potential anticancer agents. |
| AID1074220 | Aqueous solubility of the compound after 24 hrs by LC/CLND analysis | 2014 | Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
| Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT). |
| AID1188765 | Cytotoxicity against human HepG2 cells after 24 hrs by SRB assay | 2014 | European journal of medicinal chemistry, Oct-30, Volume: 86 | Synthesis of novel 1,2,4-triazoles, triazolothiadiazines and triazolothiadiazoles as potential anticancer agents. |
| AID1564560 | Toxicity in Crl:CD Sprague-Dawley rat heart assessed as increase in cardiomyocytes cytoplasmic vacuolation at 200 mg/kg, po administered once daily for 5 days via gavage by hematoxylin and eosin staining based microscopic analysis | 2019 | European journal of medicinal chemistry, Nov-01, Volume: 181 | Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group. |
| AID1564562 | Antitumor activity against mouse 4T1 cells implanted in BALB/c mouse assessed as reduction in tumor weight at 10 mg/kg, ip bid for 12 days | 2019 | European journal of medicinal chemistry, Nov-01, Volume: 181 | Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group. |
| AID1454317 | Inhibition of C-terminal His-tagged human recombinant NAMPT using FK866 or isoindoline urea-based Oregon green (488) probe incubated for 3 hrs by TR-FRET assay | 2017 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
| SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT). |
| AID1564563 | Antitumor activity against mouse 4T1 cells implanted in Balb/c mouse mouse assessed as inhibition of tumor metastasis at 10 mg/kg, ip bid for 12 days measured post last dose by crystal violet staining based thioguanine clonogenic assay | 2019 | European journal of medicinal chemistry, Nov-01, Volume: 181 | Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group. |
| AID146711 | Cytotoxic activity against NUGC gastric cancer cell line | 2004 | Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
| Synthesis and in vitro cytotoxicity of 5-substituted 2-cyanoimino-4-imidazodinone and 2-cyanoimino-4-pyrimidinone derivatives. |
| AID1188762 | Cytotoxicity against human NUGC cells after 24 hrs by SRB assay | 2014 | European journal of medicinal chemistry, Oct-30, Volume: 86 | Synthesis of novel 1,2,4-triazoles, triazolothiadiazines and triazolothiadiazoles as potential anticancer agents. |
| AID1057516 | Inhibition of NAMPT in human HepG2 cells using [14C]-nicotinamide/PRPP as substrate assessed as formation of [14C]-nicotinamide mononucleotide after 1 hr by liquid scintillation counting analysis | 2013 | Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
| Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship. |
| AID1347110 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347129 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347112 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347118 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347113 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347109 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347117 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347127 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347125 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347122 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347121 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347115 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347128 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347126 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347124 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347116 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347111 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347123 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347114 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347119 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1800299 | NAMPT enzyme assay from Article 10.1002/cbic.201402023: \\Structural and biochemical analyses of the catalysis and potency impact of inhibitor phosphoribosylation by human nicotinamide phosphoribosyltransferase.\\ | 2014 | Chembiochem : a European journal of chemical biology, May-26, Volume: 15, Issue:8
| Structural and biochemical analyses of the catalysis and potency impact of inhibitor phosphoribosylation by human nicotinamide phosphoribosyltransferase. |
| AID1799546 | In Vitro Inhibition Assay from Article 10.1016/j.chembiol.2010.05.008: \\Chemical proteomics identifies Nampt as the target of CB30865, an orphan cytotoxic compound.\\ | 2010 | Chemistry & biology, Jun-25, Volume: 17, Issue:6
| Chemical proteomics identifies Nampt as the target of CB30865, an orphan cytotoxic compound. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |